Nerve Growth Factor Regulates Adrenergic Expression

T. C. Tai, David C. Wong-Faull, Robert Claycomb, and Dona L. Wong

Department of Psychiatry, Harvard Medical School and Laboratory of Molecular and Developmental Neurobiology, McLean Hospital, Belmont, Massachusetts

Received May 2, 2006; accepted August 22, 2006

ABSTRACT

The mechanism by which nerve growth factor (NGF) regulates adrenergic expression was examined in PC-12 cells transfected with a rat phenylethanolamine N-methyl-transferase (PNMT) promoter-luciferase reporter gene construct pGL3RP893. NGF treatment increased PNMT promoter-driven luciferase activity in a dose- and time-dependent manner. Induction was attenuated by inhibition of the extracellular signal-regulated kinase mitogen-activated protein kinase (MAPK) pathway (~60%) but not by inhibition of the protein kinase A (PKA), protein kinase C, phosphoinositol kinase, or p38 MAPK pathways. Deletion PNMT promoter-luciferase reporter gene constructs showed that the NGF-responsive sequences lay within the proximal ~392 base pairs (bp) of PNMT promoter, wherein binding elements for Egr-1 (~165 bp) and Sp1 (~48 bp) reside. Western analysis further showed that NGF increased nuclear levels of Egr-1, but not Sp1 or the catalytic subunit of PKA. Gel mobility shift assays showed increased potential for Egr-1, but not Sp1, protein-DNA binding complex formation. Mutation of either the Egr-1 or Sp1 binding sites in the PNMT promoter attenuated NGF activation. NGF, combined with putative adenyl cyclase-activating protein (PACAP), another PNMT transcriptional activator, cooperatively stimulated PNMT promoter driven-luciferase activity beyond levels observed with either neurotrophin alone. Finally, post-transcriptional control seems to be another important mechanism by which neurotrophins regulate the adrenergic phenotype. NGF, PACAP, and a combination of the two stimulated both intron-retaining and intronless PNMT mRNA and PNMT protein, but to different extents.

Phenylethanolamine N-methyltransferase (PNMT; EC 2.1.1.28), the final enzyme in catecholamine biosynthesis, converts norepinephrine to epinephrine, thereby serving as a marker of the adrenergic phenotype (Wong, 2003). PNMT is expressed predominantly in adenal medullary chromaffin cells (Anderson, 1993), with limited expression in specific brainstem neurons (Foster et al., 1985) and cardiac myocytes (Ebert et al., 1996).

Adrenal chromaffin cells arise from sympathoadrenal progenitors of neural crest derivation. Neurotrophic factors, such as nerve growth factor (NGF), promote sympathoadrenal progenitor cell differentiation to sympathetic neurons and ensure survival of the latter (Anderson, 1993). In general, preganglionic sympathetic neurons innervate postganglionic noradrenergic neurons and noradrenergic and adrenergic chromaffin cells in the adrenal medulla (Muller and Unsicker, 1986; Anderson, 1993). Although NGF and other neurotrophins are present in developing and mature adrenal chromaffin cells (Suter-Crazzolara et al., 1996), their ability to regulate adrenergic expression in these cells seems controversial. NGF has been shown to increase PNMT activity in bovine chromaffin cells (Acheson et al., 1984), but not rat chromaffin cells (Muller and Unsicker, 1986). It does not seem to induce PNMT expression in PC-12 cells derived from rat adrenal medullary pheochromocytomas (Unsworth et al., 1999).

The neuropeptide pituitary adenyl cyclase-activating polypeptide (PACAP) is another potent neurotrophin involved in the differentiation of sympathoadrenal cell lineage (Grumolato et al., 2003), and it functions as a neurotransmitter as well when released from the splanchnic nerve in-
neruating the adrenal medulla (Guo and Wakade, 1994). In cultured adrenal bovine chromaffin cells, PACAP increases the expression of all the catecholamine biosynthetic enzyme genes, including that of PNMT (Choi et al., 1999), and has been shown to stimulate PNMT promoter-driven luciferase activity in PC-12 cells transfected with rat PNMT-promoter luciferase reporter gene constructs (Wong et al., 2002). Recent findings suggest that in their developmental role as neurotrophins, NGF and PACAP may act in a complementary manner during the differentiation of sympathoadrenal cells based on common and separate effects on neuroendocrine and neural marker genes and associated transcription factors (Grumolato et al., 2003). However, whether they function together to regulate adrenergic expression is unknown.

The current study was undertaken to delineate the effects of NGF on adrenergic expression, to investigate the underlying mechanism for NGF-induced changes, and to determine whether NGF and PACAP act cooperatively to control adrenergic function. Results show that NGF increases rat PNMT promoter-driven gene transcription in PC-12 cells. NGF induction of PNMT promoter activity is mediated via extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) via downstream effects on the PNMT gene transcriptional activators Egr-1 and Sp1. In addition, NGF can interact with the poly peptide PACAP to synergistically activate PNMT promoter-driven gene expression beyond activation that occurs with either neurotrophin alone. Finally, both NGF and PACAP induce two forms of PNMT mRNA in PC-12 cells, intron-retaining and intronless (Unsworth et al., 1999), but together they ensure PNMT primary transcript splicing predominantly to fully processed message.

Materials and Methods

Cell Culture. Rat pheochromocytoma-derived PC-12 cells (from Dr. Daniel O’Connor, Department of Medicine, University of California, San Diego, CA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 5% equine serum (Hyclone Laboratories, Logan, UT), 5% bovine calf serum (Hyclone Laboratories) and gentamicin sulfate (50 µg/ml; Sigma-Aldrich, St. Louis, MO) and maintained in a humidified incubator at 37°C under an atmosphere of 5% CO2, 95% air (Tai et al., Sigma-Aldrich, St. Louis, MO) and maintained in a humidified incubator at 37°C under an atmosphere of 5% CO2, 95% air (Tai et al., 2003); and U-73122 (50 µM), an adenylate cyclase activator; GF109203X (100 nM), a selective protein kinase A (PKA) inhibitor (Chijiwa et al., 1990; Tai and Wong, 2002); forskolin (10 µM), an adenylate cyclase activator; GF109203X (100 nM), a protein kinase C (PKC) inhibitor (Tsujii et al., 2001; Tai and Wong, 2002); phorbol 12-myristate 13-acetate (PMA; 80 nM), a PKC activator; and 200 µl of cell lysis buffer by subjecting them to a freeze-thaw cycle. Lysates were centrifuged (1000g for 10 min), and 20 µl of supernatant was assayed for luciferase activity as described previously (Ebert et al., 1994) using a microplate luminometer (Dynex Technologies, Chantilly, VA). Protein in the cell lysates was quantified by the method of Bradford (Bradford, 1976), and luciferase activity was expressed per microgram of protein. β-Galactosidase activity was determined to correct for variation in transfection efficiency (Ebert et al., 1994), and luciferase activity was expressed relative to β-galactosidase. The ratio of luciferase to β-galactosidase activity for the wild-type or the mutant deletion PNMT promoter-luciferase reporter gene construct, as appropriate, was set to unity, and all values from treatment samples expressed relative to it.

Cytosolic and Nuclear Protein Extraction. Protein extracts from PC-12 cells were prepared as described previously (Tai et al., 2001). In brief, after treatment with 50 ng/ml NGF, 10 nM PACAP, or the combination, cells were washed with ice-cold PBS, pelleted in microfuge tubes by centrifugation (1000g for 5 min), and lyzed by resuspension in 100 µl of 10 mM HEPES-KOH, pH 7.9, containing 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, and protease inhibitors (Complete Mini EDTA-free protease inhibitor cocktail tablets; Boehringer Ingelheim USA, Ridgefield, CT). After incubation on ice for 10 min, nuclei were collected by centrifugation (1000g for 5 min), and the supernatant was retained as cytosolic protein extract. Pelleted nuclei were then lysed by resuspension in 100 µl of 20 mM HEPES-KOH, pH 7.9, containing 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, and protease inhibitors. Nuclear protein extract was isolated as the supernatant recovered after centrifugation (17,000g for 2 min) at 4°C. Protein concentrations for cytosolic and nuclear extracts were determined as described above and stored at −70°C until use.

Western Blot Analysis. Cytosolic or nuclear proteins (10–20 µg) were resolved on 10 to 12% SDS-polyacrylamide gels and then transferred to nitrocellulose membranes (Tai et al., 2001). Membranes were blocked overnight at 4°C with 10% skim milk in 20 mM Tris-HCl, 137 mM NaCl, and 0.05% Tween 20, pH 7.2 (TBS-T). After washing with TBS-T (one time for 15 min, two times for 10 min each at room temperature), membranes derived from cytosolic extracts were incubated with anti-bovine PNMT antibody (1:5000; Wong et al., 1987), whereas membranes derived from nuclear extracts were incubated with rat polyclonal Egr-1 (1:1000, C-19; Santa Cruz Bio-technology, Inc., Santa Cruz, CA), Sp1 (1:5000, PEP2; Santa Cruz Biotechnology, Inc.), or mouse monoclonal catalytic subunit of PKA (PKA-C) (1:500; BD Biosciences Transduction Laboratories, Lexington, KY) antibodies for 1 h at room temperature. Membranes were then again washed with TBS-T (one time for 15 min, two times for 10 min
each) and then incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (1:5000; Santa Cruz Biotechnology, Inc.) as appropriate for 1 h at room temperature. After a final wash with TBS-T (one time for 15 min, two times for 10 min each), proteins were detected by enhanced chemiluminescence (Santa Cruz Biotechnology, Inc.) using Hyperfilm (GE Healthcare, Little Chalfont, Buckinghamshire, UK).

**Gel Mobility Shift Assay.** Gel mobility shift assays (GMSAs) were performed using the nuclear protein extracts described above and double-stranded oligonucleotides encoding the −165-bp Egr-1 binding element in the rat PNMT promoter (5′-CCTCCGCGG-TCCCCGCGTC3′, −160 to −180 bp) (Ebert et al., 1994) or a consensus Sp1 binding element (5′-TAGAGGGGGGGGTTCTGAC-3′; Christy and Nathans, 1989) 5′ end-labeled with [γ-32P]dATP using T4 polynucleotide kinase as described previously (Ebert et al., 1994; Tai et al., 2001). Protein-DNA complexes were separated on 5% polyacrylamide gels and visualized by autoradiography using Kodak X-Omat LS film (Fisher Scientific, Springfield, NJ).

**Reverse Transcription-Polymerase Chain Reaction.** Radioactive reverse transcription-polymerase chain reaction (RT-PCR) was performed as described previously (Her et al., 2003). In brief, total RNA was extracted from control and drug-treated PC-12 cells using Tri-Reagent (Sigma-Aldrich) as per the manufacturer. All samples were treated with DNaseII (1 unit/2 μg of total RNA; Ambion, Austin, TX) for 30 min at 37°C before use. One microgram of total RNA was reverse transcribed with StrataScript (Stratagene, La Jolla, CA) according to the vendor. PCR was performed in a total volume of 25 μl containing 100 ng of reverse transcriptase product, 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl2, 200 nM dNTPs, 0.2 μM sense and antisense primers, 0.1 μCi of [α-32P]dATP, and 2 units of Taq DNA polymerase (Promega, Madison, WI). The following primer sets were used for PNMT and glyceraldehyde-3-phosphate dehydrogenase (GAPDH): PNMT: sense, 5′-CAGACTCTCCTG-GAGGTCACCTTG-3′ and antisense, 5′-TTATAGGTGGCACCCTCG-GGTG-3′; GAPDH: sense, 5′-ATGCTGGTGCTAGTGTGCG-3′ and antisense, 5′-CATGTGACATCCCAAGGGGATAC-3′.

Reactions were incubated for 1 min at 94°C, 1 min at 61°C, and 1 min at 72°C in a PTC-200 DNA Engine thermocycler (MJ Research, Watertown, MA), repeating these cycles 35 times for PNMT and 18 times for GAPDH. PNMT and GAPDH amplicons were combined, resolved on 5% polyacrylamide gels, and visualized by autoradiography.

**Data Analysis.** All data are presented as the mean ± S.E.M. Experiments were repeated at least three times, with six replicates per group. Statistical significance between experimental and control groups was determined by one-way analysis of variance followed by post hoc comparisons using Student-Newman-Keuls multiple comparisons test to compare values against each other or Dunnett’s comparison test to compare treatment groups against controls. Values of p < 0.05 were considered statistically significant.

**Results**

**NGF Activation of the PNMT Promoter.** To determine the effects of NGF on adrenergic expression, PC-12 cells transfected with a construct containing the proximal 893 bp of the rat PNMT promoter (Fig. 1A) upstream of the firefly luciferase reporter gene (pGL3RP893) were treated with varying concentrations of NGF up to 100 ng/ml, and PNMT promoter-driven luciferase reporter gene expression was de-
terminated after 24 h (Fig. 1B). NGF activated the PNMT promoter in a dose-dependent manner with induction reaching maximum values between 5 and 100 ng/ml. Because the 50 ng/ml concentration is consistent with previously reported investigations, it was used for all subsequent studies (Unsworth et al., 1999).

A time course for NGF induction was then performed. As shown in Fig. 1C, NGF increased luciferase activity ~3.0-fold at 6 h. Luciferase expression was even higher at 24 h, with an ~6.0-fold elevation above basal levels and a 2.0-fold higher increment than that observed at 6 h. Thus, NGF stimulates PNMT promoter-driven gene transcription in both a dose- and time-dependent manner.

**Signaling Pathways Associated with NGF Activation of the PNMT Promoter.** NGF activates several intracellular signaling pathways in PC-12 cells, including those of PKA, PKC, p38, and ERK1/2 MAPK (Schubert et al., 1977; Hama et al., 1986; Xing et al., 1996). To determine whether any of these might be involved in NGF activation of the PNMT gene promoter, the effects of specific inhibitors and activators of these pathways were examined in PC-12 cells transfected with the pGL3RP893 construct. Pretreatment of cells with the PKA inhibitor H89 (30 μM) for 1 h did not alter NGF activation of the PNMT promoter (Fig. 2A), but treatment of the transfected cells with NGF in combination with the adenylate cyclase activator forskolin (10 μM) increased luciferase activity beyond the additive effects of either drug alone (~12.0- versus 5.0- and ~2.6-fold, respectively; Fig. 2B). Likewise, the PKC inhibitor GF109203X (100 nM) had no significant effect on NGF activation of the PNMT promoter (Fig. 3A), whereas the PKC activator PMA potentiated NGF-induced PNMT promoter-driven gene expression, increasing luciferase ~2.5-fold beyond levels observed with NGF alone (Fig. 3B). However, in contrast to forskolin, PMA

![Graph A](image)

![Graph B](image)

**Fig. 2.** Role of cAMP-PKA pathway in NGF activation of the PNMT promoter. A, PC-12 cells transfected with pGL3RP893 PNMT were pretreated with the PKA inhibitor H89 (30 μM) for 1 h, followed by 50 ng/ml NGF for 24 h. B, PC-12 cells transfected with pGL3RP893 were treated with 50 ng/ml NGF and/or the adenylate cyclase activator forskolin (10 μM) for 24 h. Luciferase activity was determined and expressed relative to untreated control values set to unity. Data are expressed as the mean ± S.E.M. (n = 6; significantly different from respective control: ++++, p ≤ 0.001; significantly different within a treatment group: +++, p ≤ 0.001). Experiments were replicated at least three times.

![Graph A](image)

![Graph B](image)

**Fig. 3.** Role of PKC pathway in NGF activation of the PNMT promoter. A, PC-12 cells transfected with pGL3RP893 were pretreated with the PKC inhibitor GF109203X (100 nM) for 1 h followed by 50 ng/ml NGF for 24 h. B, PC-12 cells transfected with pGL3RP893 were treated with 50 ng/ml NGF and/or the PKC activator PMA (80 nM) for 24 h. Luciferase activity was determined and expressed relative to untreated control values set to unity. Data are expressed as the mean ± S.E.M. (n = 6; significantly different from respective control: ++++, p ≤ 0.001; significantly different within a treatment group: +++, p ≤ 0.001). Experiments were replicated at least three times.
did not independently activate the PNMT promoter. Pre-treatment of the transfected cells with the p38 MAPK inhibitor SB203580 (10 \mu M); two phosphoinositide kinase inhibitors, wortmannin (0.1–1.0 \mu M) and LY294002 (10–50 \mu M); or the phospholipase C inhibitor U-73122 (5 \mu M) did not attenuate NGF induction of the PNMT promoter as well (data not shown), but the MEK inhibitor U0126 (10 \mu M), which inhibits the ERK1/2 pathway, reduced the NGF-mediated increase in luciferase activity by \( \sim 60\% \) (Fig. 4). Thus, PNMT promoter activation by NGF seems orchestrated in part through activation of the ERK1/2 MAPK pathway, but it does not directly involve the p38, PKA, PKC, phosphoinositide kinase, or phospholipase C pathways. In addition, PKA and PKC pathway activation apparently can act cooperatively to potentiate NGF stimulation of PNMT promoter-driven transcription.

**NGF Responsive Regions in the PNMT Promoter.** To identify DNA sequences within the proximal \( \sim 893 \) bp of the PNMT promoter sensitive to NGF stimulation, nested deletion mutant PNMT promoter-luciferase reporter gene constructs generated by 5′ exonuclease digestion of the PNMT promoter were transfected into PC-12 cells, and the effects of NGF on promoter activity were examined (Fig. 5). NGF induction of PNMT promoter-driven luciferase expression for each of the deletion constructs was expressed relative to respective control, because we have previously shown that basal luciferase activity for each construct varies depending on the complement and amount of transcription factors present in the cells relative to the corresponding binding elements within the promoter sequences of interest (Her et al., 1999). No significant differences were observed in NGF activation of luciferase in cells transfected with the wild-type pGL3RP1833 construct or two of the truncated constructs, pGL3RP442 and pGL3RP392. However, a marked attenuation in luciferase induction (\( \sim 63\% \)) by NGF was observed with the shortest construct, pGL3RP60. Thus, the DNA sequences proximal to \( \sim 392 \) bp are probably important for the effects of NGF on PNMT promoter-driven gene expression.

**Role of Egr-1 and Sp1 in NGF Activation of the PNMT Promoter.** The proximal \( \sim 392 \) bp of the rat PNMT promoter contains functional consensus binding elements for the immediate early gene transcription factor Egr-1 (\( \sim 165 \) bp) and the ubiquitous transcription factor Sp1 (\( \sim 148 \) and \( \sim 48 \) bp), with the \( \sim 48 \) bp Sp1 site being the more functionally significant (Ebert et al., 1994). The effects of NGF on nuclear Egr-1 and Sp1 expression were therefore examined by analyzing nuclear protein extracts from control or NGF-treated PC-12 cells by Western blot analysis using primary antibodies specific for each transcription factor. Changes in nuclear levels of PKA-C were concurrently examined to confirm that PKA signaling does not contribute to NGF-induced PNMT promoter activity. As shown in Fig. 6A, basal levels of Egr-1 protein are very low in PC-12 cell nuclei, but NGF treatment of the cells markedly and rapidly induces nuclear expression of this transcription factor. Changes in Egr-1 are time-dependent and transient, with maximum stimulation occurring at 60 min, followed by restoration to basal values by 240 min after initial drug exposure. In contrast, nuclear levels of Sp1 in the PC-12 cells are very high, but expression of this transcription factor is not altered by exposure of the cells to NGF. In addition, NGF had no effect on nuclear expression of PKA-C, consistent with the absence of PKA participation in NGF activation of the PNMT promoter.

Because both Egr-1 and Sp1 must be phosphorylated to bind to their consensus elements and activate gene expression and antibodies specific for the phosphorylated transcription factors were unavailable, nuclear extracts isolated from NGF-treated PC-12 cells were also assessed for Egr-1 and Sp1 protein-DNA complex formation using GMSAs (Fig. 6B). Although protein-DNA complex formation for control samples using the double-stranded oligonucleotide containing the \( \sim 165 \) bp Egr-1 binding element from the rat PNMT promoter was below the detection sensitivity of the GMSA assay, a very strong protein-DNA complex band was observed using nuclear extracts from NGF-treated PC-12 cells. Previous GMSA analysis using this oligonucleotide probe and Egr-1 antibodies demonstrated that for PC-12 cells, the
protein bound is Egr-1 (Tai et al., 2001). In contrast, no change in protein-DNA complex formation was apparent in GMSAs performed with the Sp1 double-stranded oligonucleotide, a probe shown to be specific for Sp1 protein binding with PC-12 cells (Her et al., 1999).

To further investigate the role of Egr-1 and Sp1 in NGF-mediated PNMT promoter-driven gene expression, the effects of mutation of the −165-bp Egr-1 (pGL3RP893mutEgr-1), the −168-bp Sp1 (pGL3RP893mutSp1A), the −48-bp Sp1 (pGL3RP893mutSp1B), or both Sp1 sites (pGL3RP893mutSp1A/B) on NGF-elicited responses were assessed in transient transfection assays. As with the deletion mutants, luciferase activity was expressed relative to respective unstimulated controls to ensure correction for any differences in basal luciferase activity due to the mutations. Mutation of the −165-bp Egr-1 site attenuated NGF stimulation of the PNMT promoter ~38% (Fig. 7A), whereas mutation of the upstream −168-bp Sp1 site decreased PNMT promoter activation 24%. However, when the proximal −48 bp Sp1 site or both Sp1 sites were mutated, NGF induction of the PNMT promoter was eliminated (Fig. 7B).

Cooperative Induction of PNMT Promoter-Driven Gene Expression by NGF and PACAP. Recent findings suggest that NGF and PACAP can act additively or cooperatively to regulate cellular processes, including gene expression (Hashimoto et al., 2000; Sakai et al., 2001; Grumolato et al., 2003; Yuhara et al., 2003). Because PACAP, like NGF, also activates PNMT promoter-driven gene transcription (Wong et al., 2002), the combined effect of NGF and PACAP on PNMT promoter activity was examined in PC-12 cells transfected with the pGL3RP893 construct (Fig. 8A). Although NGF (50 ng/ml) and PACAP (10 nM) independently stimulated luciferase activity 6.5- and ~5.0-fold, respectively, in the transfected PC-12 cells after 24 h of drug exposure, simultaneous treatment with these neurotrophins increased luciferase activity ~16.0-fold. Thus, NGF and PACAP apparently interact synergistically to stimulate PNMT promoter-driven gene expression beyond the independent activation by either alone.

As shown in Fig. 2, the adenylate cyclase activator forsko-

Fig. 6. Effect of NGF on Egr-1 and Sp1 protein and protein-DNA complex formation. A, PC-12 cells were treated with 50 ng/ml NGF for 0 to 360 min, and nuclear protein extracts were prepared and separated on 10% SDS-polyacrylamide gels, followed by enhanced chemiluminescence Western analysis with PKA-C (1:500; BD Transduction Laboratories), Egr-1 (1:1000; Santa Cruz Biotechnology, Inc.), and Sp1 (1:5000; Santa Cruz Biotechnology, Inc.) antibodies. Representative fluorogram from three replicates. B, Nuclear extracts isolated from PC-12 cells exposed to NGF for 60 min were subjected to GMSA analysis using 32P-labeled double-stranded oligonucleotides encoding the −165-bp Egr-1 binding element in the PNMT promoter (5′-CTCCCCCGCCCGCGTCC-3′) and consensus Sp1 binding element (5′-TAGAGGGCGGGCTCTAGAC-3′) as described under Materials and Methods. Protein-DNA complexes, after separation on 5% polyacrylamide gels, were visualized by autoradiography.

Fig. 7. Role of Egr-1 and Sp1 in NGF activation of the PNMT promoter. A, PC-12 cells were transfected with the wild-type construct pGL3RP893 or a construct containing a mutated −165 bp Egr-1 binding element, pGL3RP893mutEgr-1. After transfection, cells were treated with 50 ng/ml NGF for 24 h. Luciferase activity was determined and expressed relative to untreated control values set to unity. Data are presented as the mean ± S.E.M. (n = 6; significantly different from respective control: ***, p < 0.001; significantly different within NGF treatment group: +, p < 0.01; significantly different from respective control: ***, p < 0.001; significantly different within NGF treatment group: +, p < 0.01). Experiments were replicated at least three times. B, PC-12 cells were transfected with the wild-type construct pGL3RP893 or constructs containing mutations in the −168-bp (pGL3RP893mutSp1A), −48-bp (pGL3RP893mutSp1B), or both (pGL3RP893mutSp1A/B) Sp1 binding sites and treated with 50 ng/ml NGF for 24 h. Luciferase activity was determined and expressed relative to untreated control values set to unity. Data are expressed as the mean ± S.E.M. (n = 6; significantly different from respective control: * * p < 0.05; ***, p < 0.001; significantly different from pGL3RP893mutSp1A: a, p < 0.001; significantly different from pGL3RP893mutSp1B: b, p < 0.001.
lin incrementally elevated PNMT promoter-driven luciferase reporter gene expression in PC-12 cells above the rise induced by NGF alone. One of the major signal transducers associated with PACAP-mediated gene activation is cAMP via both PKA-dependent and -independent pathways (Vaudry et al., 2002). To further examine the role of adenylate cyclase and cAMP in the synergistic activation of PNMT promoter-driven gene expression, pGL3RP893-transfected PC-12 cells were pretreated with 30 μM H89 for 1 h, followed by treatment with 50 ng/ml NGF and 10 nM PACAP or the combination for 24 h (Fig. 8B). H89 did not inhibit NGF-mediated PNMT promoter stimulation as shown earlier and only partially attenuated PNMT promoter induction by PACAP (p ≤ 0.01) or the combination of NGF and PACAP (p ≤ 0.01). These results suggest that synergistic effects of NGF and PACAP on the PNMT promoter are evoked through cAMP/PKA-dependent as well as cAMP/PKA-independent signaling mechanisms.

Effect of NGF and PACAP on Endogenous PNMT mRNA and Protein Expression. To demonstrate that NGF and PACAP are important and effective regulators of the endogenous PNMT gene as well, PNMT mRNA was quantified in total RNA isolated from PC-12 cells treated with NGF, PACAP, or the combination of NGF and PACAP for 24 h using radioactive RT-PCR (Fig. 9). As reported previously (Unsworth et al., 1999), PC-12 cells express very low levels of the two forms of PNMT mRNA, intron-retaining and intronless (fully processed message). NGF treatment increased the expression of both forms, with fully processed PNMT mRNA being the predominant species. PACAP treatment increased both forms of PNMT mRNA as well, but to an equivalent extent. When cells were treated with NGF and PACAP together, two forms of PNMT mRNA were again detectable, but PACAP seemed to limit PNMT mRNA induction. Intronless message levels were equal to those observed with PACAP alone, whereas intron-retaining PNMT mRNA was lower.

PNMT protein was also examined in cytosolic protein extracts isolated from identically treated cells to determine whether mRNA and protein changes corresponded. As shown in Fig. 9, PNMT protein, similar to PNMT mRNA, was barely detectable in PC-12 cells. Treatment with NGF, PACAP, or the combination increased PNMT expression markedly. Together, these findings suggest disparity between transcriptional and translational changes, indicating that post-transcriptional events impose additional constraints on PNMT expression.

Discussion

Neurotrophic factors such as NGF promote the differentiation of sympathoadrenal progenitor cells into sympathetic neurons and are also capable of dedifferentiating chromaffin cells toward a sympathetic neuronal phenotype, whereby they lose their competence to express PNMT (Anderson,
And, PNMT activity can be detected in the sympathetic ganglia of neonatal and adult rats and increases in response to NGF treatment (Liuzzi et al., 1977a,b). Likewise, NGF can induce PNMT activity in the rat adrenal medulla (Angeletti et al., 1972) and in cultured bovine adrenal chromaffin cells (Acheson et al., 1984), and it also increases steady-state levels of PNMT mRNA expression in PC-12 cells (Unsworth et al., 1999). The present study now provides evidence that these changes in NGF-regulated adrenergic expression in PC-12 cells are at least in part mediated through an increase in PNMT promoter-driven gene transcription. Furthermore, although NGF activates a number of intracellular signaling pathways, including those of PKA (Schubert et al., 1977; Gur et al., 2002; Vaudry et al., 2002), PKC (Hama et al., 1986; Gur et al., 2002; Sakai et al., 2004), p38 MAPK (Xing et al., 1996; Dohi et al., 2002; Gur et al., 2002; Vaudry et al., 2002; Sakai et al., 2004), and ERK1/2 MAPK (Xing et al., 1996; Dohi et al., 2002; Gur et al., 2002; Vaudry et al., 2002; Sakai et al., 2004), only the ERK1/2 MAPK pathway seems involved in PNMT promoter activation by NGF. In the case of PKA and PKC signaling, we provide direct evidence that activation of these pathways produces an incremental rise in NGF-mediated PNMT promoter-driven luciferase expression (Figs. 2 and 3).

Deletion mutation analysis of the rat PNMT promoter further revealed that the DNA sequences conferring NGF sensitivity reside within the proximal −392 bp of sequence upstream of the transcription initiation start site. This same region has previously been implicated in the CAMP sensitivity of the PNMT gene (Tai et al., 2001). It contains a consensus binding site for the immediate early gene transcription factor Egr-1 at −165 bp (Ebert et al., 1994), which if mutated, markedly attenuates the cAMP-responsiveness of the PNMT promoter (Tai et al., 2001; Wong and Tai, 2002). Although the present study also implicates Egr-1 in NGF-mediated activation of the PNMT promoter, ERK1/2 MAPK pathway signaling seems to underlie Egr-1 induction of these changes. The latter agrees with earlier reports demonstrating that NGF stimulation of Egr-1 expression in PC-12 cells (Sukhatme et al., 1988) can occur via ERK1/2 MAPK (Harada et al., 2001), independent of PKA (Ginty et al., 1991), and is a key step in NGF-mediated neuritogenesis of PC-12 cells to sympathetic-like neurons. However, these results do not preclude the possibility that sequences upstream of the Egr-1 site may also be required for NGF activation, one candidate being the glucocorticoid receptor (GR) (Tai et al., 2002). We have previously shown that Egr-1 bound to the −165-bp consensus element can interact cooperatively with GRs bound to overlapping glucocorticoid response elements at −773 and −759 bp to markedly stimulate PNMT promoter-driven luciferase expression beyond levels observed with either transcription factor alone.

In the presence of a mutated −165-bp Egr-1 site, residual NGF activation of PNMT promoter-driven luciferase expression was still apparent, suggesting that other transcription factor(s) may bind to DNA elements within the proximal −392 bp of promoter sequences to contribute to NGF induction of the promoter. The zinc finger protein Sp1 participates in the transcriptional regulation of several other NGF-responsive genes (Liu et al., 2001; Melnikova and Gardner, 2001). Functional Sp1 binding elements are located at −48 and −168 bp in the rat PNMT promoter (Ebert and Wong, 1995), and we have shown that the −48 bp Sp1 site contributes to the cooperative activation of the PNMT promoter by PKA and PKC (Tai and Wong, 2003). Although NGF did not alter Sp1 protein levels in PC-12 cells, Sp1 must be phosphorylated to bind to its consensus element and activate transcription (Kadonaga et al., 1987; Her et al., 2003; Tai and Wong, 2003), and recent findings indicate that NGF does increase Sp1-DNA binding (Liu et al., 2001; Melnikova and Gardner, 2001). The present study showed that site-directed mutation of the −168-bp Sp1 site attenuated NGF activation of the PNMT promoter, whereas mutation of the −48 bp Sp1 site or both Sp1 sites eliminated NGF activation. Thus, the Sp1 binding sites are apparently necessary for maximum PNMT promoter induction. However, no changes in Sp1-DNA complex formation were observed after NGF treatment. Together, these results suggest several possibilities. First, Sp1 may subserve a permissive role in stimulus-induced PNMT promoter activation. Consistent with the latter possibility, we have previously shown that the shortest PNMT promoter sequence permitting reporter gene expression is the 60 bp of sequence proximal to the site of transcription initiation (+1) (Ebert et al., 1994) containing the −48-bp Sp1 consensus element (Her et al., 2003). Second, the upstream −168-bp Sp1 and −165-bp Egr-1 sites overlap so that Sp1 and Egr-1 can compete for binding. However, this distal Sp1/Egr-1 site predominantly functions as an Egr-1 element (Ebert et al., 1994; Ebert and Wong, 1995) in agreement with the findings reported here, albeit elimination of both Sp1 sites does prevent NGF activation. Overlapping Sp1/Egr-1 binding elements are a common motif, and Sp1 and Egr-1 competition for binding is thought to be an important gene regulatory mechanism (Her et al., 2003). This motif occurs in the PNMT promoter of other species as well (mouse, −45/−43 and −165/−162; human, −93/−92, and bovine, −90/−89) as identified through TRANSFAC version 6.0 database analysis. In these species, the PNMT gene shares 58, 41, and 51% identity, respectively, with the rat gene in the 5′ and 3′ noncoding and intronic sequences and 90, 76, and 83% identity, respectively, in the coding region (Suh et al., 1994).

Thus, activation of the PNMT promoter by NGF seems to be an important biological mechanism for regulating adrenergic responses. Third, we have demonstrated previously that several of the PNMT transcriptional activators, depending on the particular stimulus, seem to interact cooperatively to activate the PNMT promoter. Sp1, Egr-1, the GR, and AP2 bind as dimers to consensus sites in the promoter and thereby may impose alterations in promoter structure that facilitate transcription factor interaction. Finally, these possibilities are not mutually exclusive (Ebert et al., 1998; Wong et al., 1998).

Trophic factors, such as NGF, can also work cooperatively to regulate cell differentiation and function. Recent studies have shown that PACAP complements the actions of NGF in chromaffin cell development (Grumolato et al., 2003), forebrain cholinergic neuronal survival (Yuhara et al., 2003), PC-12 and hippocampal neuronal survival (Lee et al., 2002), and neuritogenesis (DiCicco-Bloom et al., 2000; Sakai et al., 2004), effects probably orchestrated through gene expression. NGF and PACAP have also been shown to cooperatively activate several genes, including the choline acetyltransferase gene (Yuhara et al., 2003) and the PACAP gene itself (Hashimoto et al., 2000; Sakai et al., 2001). Findings de-
scribed in this report now demonstrate that NGF and PACAP synergistically activate yet another gene, the PNMT gene. PACAP activation of the PNMT promoter is controlled in part through the cAMP-PKA and ERK1/2 MAPK pathways (Wong et al., 2002). Extending these findings, we demonstrate here that PKA signaling can incrementally increase PNMT promoter stimulation above levels induced by NGF via the ERK1/2 MAPK pathway, suggesting that synergistic activation of the PNMT promoter by NGF and PACAP may occur through interaction of PKA and ERK1/2 signaling. Both signal transduction pathways have previously been shown to participate in the synergistic induction of the PACAP gene (Hashimoto et al., 2000). ERK1/2 has also been shown to contribute to the synergistic effects of NGF and PACAP in cell differentiation and neurite outgrowth (Sakai et al., 2004). Studies describing cooperative neurogenesis and neuroprotective effects of NGF and PACAP suggest that the TrkA receptor may also provide cross-talk between these two neurotrophins (DiCicco-Bloom et al., 2000; Lee et al., 2002). NGF binding to TrkA rapidly activates tyrosine kinase signaling downstream. PACAP also activates tyrosine kinase activity through TrkA receptor activation, but more slowly and indirectly via PACAP type 1 receptors. Taken together, these findings suggest that activation of both convergent and divergent signaling mechanisms may account for the cooperative effects of NGF and PACAP on gene regulation and a variety of biological processes.

Finally, NGF has previously been reported to regulate PNMT gene expression via differential RNA processing in rat brainstem and adrenal medulla-derived PC-12 cells (Unsworth et al., 1999). With respect to NGF, 500- and 600-bp mRNAs are produced, the latter arising as a result of retention of intron 2. However, there is no accompanying increase in PNMT enzymatic activity in the PC-12 cells. Consistent with these findings, we show that NGF treatment of PC-12 cells stimulates the expression of both intronless and intron-containing forms of PNMT message, with the former predominating. We extend those findings by demonstrating that another neurotrophic factor, PACAP, alone or in combination with NGF, induces both forms of mRNA as well. The relative proportion of short and long forms depends on the NGF concentration and duration of exposure (data not shown). We have reported that the PNMT transcriptional activator Sp1 selectively stimulates the production of intronless PNMT mRNA (Her et al., 2003), and we are now examining its potential role in the differential processing of PNMT mRNA by NGF and PACAP. Analysis of NGF, PACAP, and NGF/PACAP-induced changes in PNMT protein further showed that these neurotrophins seem to regulate PNMT protein synthesis as well.

In summary, the neurotrophin NGF, independently and cooperatively with PACAP, regulates adrenergic expression via transcriptional and post-transcriptional control of the PNMT gene. Synergistic induction of the PNMT promoter by NGF and PACAP is mediated via the activation of the ERK1/2 MAPK and PKA pathways, with downstream participation of Egr-1 and Sp1 through their interaction with consensal binding sites at −165 bp and −168 and −48 bp, respectively. Finally, NGF and PACAP seem to further influence adrenergic expression post-transcriptionally by regulating processing of the PNMT primary transcript to intronless and intron-retaining forms of PNMT mRNA and synthesis of PNMT protein.

References


Address correspondence to: Dr. Dona L. Wong, Laboratory of Molecular and Developmental Neurobiology, Department of Psychiatry, McLean Hospital, Harvard Medical School, 115 Mill St., MRC 116, Belmont, MA 02478. E-mail: dona_wong@hms.harvard.edu